Combining baseline NT-proBNP measurement with an additional value between 24 and 96 hours significantly improved risk prediction for mortality in patients with NSTACS (P<0.001 at 48 h).
Cohort (n=455)
Do serial in-hospital measurements of NT-proBNP improve mortality risk prediction in patients with non-ST-elevation acute coronary syndrome?
Serial in-hospital NT-proBNP measurements provide independent prognostic information for mortality in NSTACS, and combining admission and a late in-hospital value improves risk prediction.
p-value: p=<0.001
UNLABELLED: There is limited information about the in-hospital plasma profile of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with non-ST-elevation acute coronary syndrome (NSTACS) and furthermore, the prognostic influence of the timing of NT-proBNP measurements in NSTACS is unsettled. These subject matters are elucidated in this study composed of 455 patients with NSTACS (symptoms <24 h). NT-proBNP was measured at 0, 6, 12, 24, 36, 48, 72 and 96 h following admission. Any death was registered at follow-up (median: 2.3 years). The study demonstrated a monophasic profile of the plasma NT-proBNP values, reaching a maximum at 6 hours, and it showed an independent prognostic significance of NT-proBNP irrespective of the sampling time. Risk prediction by NT-proBNP was improved by combining the baseline measurement and one value taken between 24 and 96 h (at 48 h, P<0.001). No additional prognostic information was provided by including more than one late in-hospital NT-proBNP value. CONCLUSIONS: The in-hospital NT-proBNP measurements exhibit a monophasic profile in patients with NSTACS and these values provide independent prognostic information as regards mortality irrespective of the sampling time. Moreover, risk prediction of NT-proBNP is strengthened by combining the admission measurement with an additional value during the hospitalization.
Nørgaard et al. (Tue,) conducted a cohort in non-ST-elevation acute coronary syndrome (NSTACS) (n=455). Serial in-hospital measurements of NT-proBNP was evaluated on Any death (p=<0.001). Combining baseline NT-proBNP measurement with an additional value between 24 and 96 hours significantly improved risk prediction for mortality in patients with NSTACS (P<0.001 at 48 h).